Literature DB >> 19062208

[Management of 315neutropenic febrile episodes in a cancer center].

H Dutronc1, M Billhot, M Dupon, H Eghbali, C Donamaria, F-A Dauchy, J Reiffers.   

Abstract

UNLABELLED: Management of febrile neutropenic patients is described in guidelines. Each cancer center can adapt these according to its local bacterial ecology. We present a retrospective study made in a cancer center from 2001 to 2003.
METHOD: Three hundred and fifteen febrile neutropenic episodes after chemotherapy (66% for solid tumor) were analysed.
RESULTS: For 279 episodes, no antibiotic therapy was given before admission. Clinical or radiological manifestations occurred in 46%; microbiologically documented infections by hemocultures in 28% (Gram positive: 42%; Gram negative: 51%) and by puncture in 14% (Gram negative: 58%). The length of pyrexia was inferior to 7 days in 88% and neutropenia inferior 7 days in 80.8%. 79.7% of episodes were treated with one of the three antibiotic therapy recommended by the center (ceftriaxone+tobramycin; ceftriaxone+ciprofloxacin; ceftriaxone+ofloxacin); 13.3% were treated with an other therapy; 7% received no antibiotic therapy. 68.5% of patients treated with one of the three antibiotic therapies, became afebrile without changing the antibiotic protocol.
CONCLUSION: In our study, there were a majority of Gram negative bacteria except for Pseudomonas aeruginosa. The three antibiotic therapy recommended by the center (third generation cephalosporin+aminoglycosides or fluoroquinolones) were effective and glycopeptide was not necessary in first intention treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19062208     DOI: 10.1016/j.medmal.2008.10.014

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  1 in total

1.  Long-term epidemiology of bacterial susceptibility profiles in adults suffering from febrile neutropenia with hematologic malignancy after antibiotic change.

Authors:  J Mebis; H Jansens; G Minalu; G Molenberghs; Wa Schroyens; Ap Gadisseur; A van de Velde; I Vrelust; H Goossens; Zn Berneman
Journal:  Infect Drug Resist       Date:  2010-07-28       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.